专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

US20060083755A1 Vaccine for feline infectious peritonitis 审中-公开
标题翻译：猫感染性腹膜炎疫苗
公开(公告)号：US20060083755A1
公开(公告)日：2006-04-20
申请号：US10520333
申请日：2003-07-04
申请人： Kenji Motokawa , Hajime Kusuhara , Hiroyuki Koyama , Tsutomu Hohdatsu , Setsuo Arai
发明人： Kenji Motokawa , Hajime Kusuhara , Hiroyuki Koyama , Tsutomu Hohdatsu , Setsuo Arai
IPC分类号： A61K48/00 , C12Q1/70 , C12Q1/68 , A61K39/12
CPC分类号： C07K14/005 , A61K39/00 , A61K39/12 , A61K39/215 , A61K2039/53 , A61K2039/552 , A61K2039/55588 , C12N2710/14143 , C12N2770/20022 , C12N2770/20034 , G01N33/56983
摘要： FIP vaccines were provided that use an N protein with a specific structure, or a fragment thereof, as an antigen. Preferred antigens of this invention are N proteins derived from a specific type I virus strain (KU-2). Vaccines comprising such an N protein confer preventive effects against a wide range of FIPVs. In addition, the N proteins are very safe because they do not comprise epitopes that enhance infection. Furthermore, preventive effects can be accomplished against type I viruses, which actually cause 70% or more of FIP.
摘要翻译：提供使用具有特定结构的N蛋白或其片段作为抗原的FIP疫苗。本发明优选的抗原是来源于特异性I型病毒株（KU-2）的N蛋白。包含这样的N蛋白质的疫苗赋予针对各种FIPV的预防效果。此外，N蛋白是非常安全的，因为它们不包含增强感染的表位。此外，可以针对实际引起70％或更多FIP的I型病毒实现预防效果。

62. 发明申请

US20060039926A1 Live attenuated Coronavirus vaccines 失效
标题翻译：活减毒冠状病毒疫苗
公开(公告)号：US20060039926A1
公开(公告)日：2006-02-23
申请号：US11135603
申请日：2005-05-23
申请人： Mark Denison
发明人： Mark Denison
IPC分类号： A61K39/215 , C12N7/00
CPC分类号： C07K14/005 , A61K2039/5254 , C12N7/00 , C12N2770/20022 , C12N2770/20061
摘要： The present invention is directed live, attenuated coronavirus vaccines. The vaccine comprises a viral genome encoding a p59 protein having at mutation at a specific tyrosine residue, and may include other attenuating mutations. Such viruses show reduced growth and pathogenicity in vivo.
摘要翻译：本发明涉及活的减毒冠状病毒疫苗。疫苗包含编码在特定酪氨酸残基处具有突变的p59蛋白的病毒基因组，并且可以包括其它减毒突变。这样的病毒在体内显示出减少的生长和致病性。

63. 发明申请

US20050276818A1 Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for SARS therapy 失效
标题翻译： SARS冠状病毒中的未表征的ORF3是环AMP-依赖性激酶和SARS治疗的靶标
公开(公告)号：US20050276818A1
公开(公告)日：2005-12-15
申请号：US11132142
申请日：2005-05-17
申请人： Adam Godzik , Sergey Sikora
发明人： Adam Godzik , Sergey Sikora
IPC分类号： A61K39/215 , C07K14/165 , C12N1/18 , C12Q1/70 , G01N33/569
CPC分类号： C07K14/005 , C12N15/1086 , C12N2770/20022 , G01N33/56983 , G01N2333/165 , G01N2500/00
摘要： The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that cause the unique infectivity activity of the SARS-coronavirus in comparison to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents which selectively inhibit cyclic-AMP dependent protein kinase activity of the SARS-coronavirus ORF3. The present invention also relates to screening assays that identify agents which selectively inhibit the interaction between SARS-coronavirus cyclic-AMP dependent protein kinase and a calcium dependent targeting molecule. Therefore the agents identified using the assays of the invention may have utility as antiviral agents. The present invention also relates to treatments for sever acute respiratory syndrome caused by a coronavirus, and particularly to treatments that affect the infectivity activity of the SARS-coronavirus. The present invention also relates to diagnostic assays for identifying and characterizing a strain of coronavirus as being one causing severe acute respiratory syndrome.
摘要翻译：本发明涉及用于鉴定抗病毒剂的新方法，其与冠状病毒的其它非SARS菌株相比选择性干扰导致SARS冠状病毒的独特感染性活性的病毒蛋白质。特别地，本发明涉及鉴定选择性抑制SARS冠状病毒ORF3的环AMP依赖性蛋白激酶活性的试剂的筛选试验。本发明还涉及鉴定选择性抑制SARS-冠状病毒环AMP依赖性蛋白激酶与钙依赖性靶向分子之间相互作用的试剂的筛选试验。因此，使用本发明的测定法鉴定的药剂可以用作抗病毒剂。本发明还涉及由冠状病毒引起的急性呼吸综合征治疗，特别涉及影响SARS冠状病毒感染性活性的治疗。本发明还涉及用于鉴定和表征冠状病毒株作为引起严重急性呼吸综合征的病毒的诊断测定法。

64. 发明申请

US20050249742A1 Compositions and methods for modulating a cytotoxic T lymphocyte immune response 审中-公开
标题翻译：用于调节细胞毒性T淋巴细胞免疫应答的组合物和方法
公开(公告)号：US20050249742A1
公开(公告)日：2005-11-10
申请号：US11022562
申请日：2004-12-22
申请人： Ruth Ruprecht , Shisong Jiang
发明人： Ruth Ruprecht , Shisong Jiang
IPC分类号： A61K38/10 , A61K39/155 , A61K39/21 , C07K14/08 , C07K14/15 , C07K14/155 , C07K14/16 , C07K14/165 , C07K14/18 , C07K14/235 , C07K14/245 , C07K14/31 , C07K14/32 , C07K14/33 , C07K14/445 , A61K39/385 , A61K39/00
CPC分类号： C07K14/005 , A61K38/10 , A61K39/12 , A61K39/155 , A61K39/21 , A61K2039/55566 , A61K2039/55572 , A61K2039/57 , A61K2039/572 , C07K14/235 , C07K14/245 , C07K14/31 , C07K14/32 , C07K14/33 , C07K14/445 , C12N2710/24143 , C12N2740/15022 , C12N2740/15034 , C12N2740/16122 , C12N2740/16222 , C12N2740/16234 , C12N2760/14122 , C12N2760/16322 , C12N2760/18522 , C12N2760/18534 , C12N2770/20022 , C12N2770/24222 , Y02A50/386 , Y02A50/388 , Y02A50/39 , Y02A50/396 , Y02A50/403 , Y02A50/41 , Y02A50/412 , Y02A50/423 , Y02A50/478
摘要： The present invention provides compositions and methods for the treatment and prevention of immune disorders.
摘要翻译：本发明提供了用于治疗和预防免疫疾病的组合物和方法。

65. 发明授权

US06913751B2 Recombinant avian herpesvirus useful in vaccine production 失效
标题翻译：用于疫苗生产的重组禽疱疹病毒
公开(公告)号：US06913751B2
公开(公告)日：2005-07-05
申请号：US09881457
申请日：2001-06-14
申请人： Mark D. Cochran , Stephanie M. Cook , Martha A. Wild
发明人： Mark D. Cochran , Stephanie M. Cook , Martha A. Wild
IPC分类号： A61K39/00 , C07K14/03 , C07K14/055 , C07K14/08 , C07K14/125 , C07K14/165 , C12N7/04 , C12N15/869 , A61K39/12
CPC分类号： C12N7/00 , A61K39/00 , C07K14/005 , C12N15/86 , C12N2710/16322 , C12N2710/16343 , C12N2710/16361 , C12N2710/16422 , C12N2760/18122 , C12N2770/20022
摘要： The present invention provides a novel avian herpesvirus (NAHV) vector and recombinant vaccines made therefrom that are useful to immunize avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease. Methods of immunizing an avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease are also provided.
摘要翻译：本发明提供了一种新型鸟类疱疹病毒（NAHV）载体和由其制备的重组疫苗，其可用于免疫禽类针对马立克氏病，感染性喉气管炎和新城疫病。还提供了免疫禽类针对马立克氏病，感染性喉气管炎和新城疫的方法。

66. 发明申请

US20050100883A1 Peptide-based diagnostic reagents for SARS 审中-公开
公开(公告)号：US20050100883A1
公开(公告)日：2005-05-12
申请号：US10712812
申请日：2003-11-12
申请人： Chang Wang , Xinde Fang , Tseng Chang , Scott Liu , Shugene Lynn , Charles Sia
发明人： Chang Wang , Xinde Fang , Tseng Chang , Scott Liu , Shugene Lynn , Charles Sia
IPC分类号： A61K38/00 , A61K38/16 , C07K14/165 , C12Q1/70 , G01N33/569
CPC分类号： C07K14/005 , A61K38/00 , C12N2770/20022 , G01N33/56983
摘要： The present invention is directed to antigenic peptides and peptide compositions selected from the Membrane glycoprotein (M), the Spike glycoprotein (S), and the Nucleocapsid (N) protein antigens of the SARS coronavirus (SCoV). The present invention is also directed to methods of use of the peptides of the invention, e.g., for the detection of SARS-associated antibodies. Detection methods include enzyme-linked immunosorbent assay (ELISA) or other immunoassay procedures.

67. 发明申请

US20050095618A1 Compositions and methods for diagnosing and treating severe acute respiratory syndrome (SARS) 有权
标题翻译：诊断和治疗严重急性呼吸综合征（SARS）的组合和方法
公开(公告)号：US20050095618A1
公开(公告)日：2005-05-05
申请号：US10901744
申请日：2004-07-28
申请人： Kwok Tsui , Kwok Fung , Mary Miu Waye , Yuk Ming Lo , Siu Chung Chim , Wai Kwun Chiu , Siu Lun Tam , Kay Sheung Chan
发明人： Kwok Tsui , Kwok Fung , Mary Miu Waye , Yuk Ming Lo , Siu Chung Chim , Wai Kwun Chiu , Siu Lun Tam , Kay Sheung Chan
IPC分类号： A61K39/00 , C07K14/165 , C12Q1/68 , A61K48/00 , C07H21/02 , C07H21/04 , C07K14/00
CPC分类号： C07K14/005 , A61K39/00 , A61K2039/53 , C12N2770/20022
摘要： The present invention relates to the fields of immunochemistry and pharmacology. Methods and compositions are described for the diagnosis and treatment of SARS CoV infection. More specifically, the application discloses nucleic acids and peptides of the spike glycoprotein of SARS CoV that provide prognostic and therapeutic compositions in treatment of individuals contracting, or in danger of contracting SARS CoV. The peptides of the invention are also useful in producing antibodies against the SARS CoV glycoprotein.
摘要翻译：本发明涉及免疫化学和药理学领域。描述了SARS CoV感染的诊断和治疗方法和组成。更具体地，该申请公开了SARS CoV的尖峰糖蛋白的核酸和肽，其提供治疗个体的预后和治疗组合物，这些个体承受或承受SARS CoV的危险。本发明的肽也可用于产生针对SARS CoV糖蛋白的抗体。

68. 发明申请

US20050058664A1 Infectious bursal disease virus (IBDV) mutant expressing virus neutralising epitopes specific for classic-and variant IBDV strains 有权
标题翻译：传染性法氏囊病病毒（IBDV）突变体表达经典和变体IBDV菌株特异性的病毒中和表位
公开(公告)号：US20050058664A1
公开(公告)日：2005-03-17
申请号：US10809176
申请日：2004-03-24
申请人： Egbert Mundt , Tobias Letzel , Guntram Paul , Adriaan Maria van Loon
发明人： Egbert Mundt , Tobias Letzel , Guntram Paul , Adriaan Maria van Loon
IPC分类号： A61K35/00 , A61K39/12 , C07K14/08 , C12N7/00 , C12N7/04 , C12Q1/70
CPC分类号： C12N7/00 , A61K35/00 , A61K39/12 , A61K2039/5252 , A61K2039/5254 , A61K2039/552 , A61K2039/55566 , C07K14/005 , C12N2720/10034 , C12N2720/10061 , C12N2770/20022
摘要： The present invention provides a classic IBDV mutant that additionally comprises virus neutralising epitopes 67 (specific for variant-E IBDV).
摘要翻译：本发明提供了另外包含病毒中和表位67（特异于变体-EBDV）的经典IBDV突变体。

69. 发明申请

US20050004063A1 Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference 有权
标题翻译：通过RNA干扰抑制SARS相关冠状病毒（SCoV）感染和复制
公开(公告)号：US20050004063A1
公开(公告)日：2005-01-06
申请号：US10848737
申请日：2004-05-19
申请人： Hsiang-Fu Kung , Ming-Liang He , Bo-Jiang Zheng , Yi Guan , Marie Lin , Ying Peng
发明人： Hsiang-Fu Kung , Ming-Liang He , Bo-Jiang Zheng , Yi Guan , Marie Lin , Ying Peng
IPC分类号： A61K39/00 , A61K48/00 , C07K14/165 , C12N15/113 , C07H21/04 , C12Q1/70
CPC分类号： C12N15/1131 , A61K39/00 , A61K48/005 , A61K2039/53 , C07K14/005 , C12N2310/111 , C12N2310/14 , C12N2770/20022
摘要： The present invention relates to therapeutic agents useful for the treatment of Severe Acute Respiratory Syndrome (SARS) in humans. In particular, the present invention relates to RNA interference (RNAi) molecules useful for inhibiting the infection and replication of hSARS virus. Preferably, the RNAi molecules target the replicase region of the hSARS virus, or combinations of different sites of hSARS virus genes. The present invention further encompasses methods of using the RNAi molecules for preventing and/or treating SARS. Vaccines and kits comprising therapeutically effective amounts of the RNAi molecules are also encompassed.
摘要翻译：本发明涉及可用于治疗人类中严重急性呼吸综合征（SARS）的治疗剂。特别地，本发明涉及可用于抑制hSARS病毒的感染和复制的RNA干扰（RNAi）分子。优选地，RNAi分子靶向hSARS病毒的复制酶区域或hSARS病毒基因的不同位点的组合。本发明还包括使用RNAi分子来预防和/或治疗SARS的方法。还包括包含治疗有效量的RNAi分子的疫苗和试剂盒。

70. 发明申请

US20040175829A1 Nucleocapsid-independent specific viral RNA packaging and uses thereof 审中-公开
标题翻译：与核衣壳无关的特异性病毒RNA包装及其用途
公开(公告)号：US20040175829A1
公开(公告)日：2004-09-09
申请号：US10794363
申请日：2004-03-05
发明人： Shinji Makino , Krishna Narayanan
IPC分类号： C12N015/86 , C12N007/00
CPC分类号： C07K14/005 , C12N15/86 , C12N2770/20022
摘要： The present invention shows that expressed coronavirus envelope protein M specifically interacted with co-expressed non-coronavirus RNA transcripts containing the short viral packaging signal in the absence of coronavirus N protein. Furthermore, this M protein-packaging signal interaction led to specific packaging of the packaging-signal-containing RNA transcripts into coronavirus-like particles in the absence of N protein. These findings highlight a novel RNA packaging mechanism for an enveloped virus, and a novel coronavirus-based expression system can be developed based on the data presented herein.
摘要翻译：本发明显示，在不存在冠状病毒N蛋白的情况下，表达的冠状病毒包膜蛋白M与包含短病毒包装信号的共表达非冠状病毒RNA转录物特异性相互作用。此外，这种M蛋白质包装信号相互作用导致在不存在N蛋白的情况下将含有包装信号的RNA转录物特异性包装到冠状病毒样颗粒中。这些发现突出显示了一种用于包膜病毒的新型RNA包装机制，并且可以基于本文提供的数据开发新颖的基于冠状病毒的表达系统。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式